Endocrine Abstracts

Objective: The aim of our study was to evaluate the possibility of maintaining the metabolic effects of liraglutide 3.0 mg treatment after it’s cessation.Methods: The study included 8 patients with type 2 diabetes (T2D) and obesity who received liraglutide 3.0 mg daily for 9 months. All of them successfully reduced body weight, insulin resistance level (IR), volume of visceral adipose tissue, HbA1c level. After discontinuation of liraglutide in 2019...